


CDK9-IN-1

Cat. No.:	HY-13231		
CAS No.:	1415559-43-1		
Molecular Formula:	C ₂₆ H ₂₁ N ₅ O ₄ S		
Molecular Weight:	499.54		
Target:	CDK; HIV		
Pathway:	Cell Cycle/DNA Damage; Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (200.18 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	Preparing Stock Solutions	1 mM		2.0018 mL	10.0092 mL	20.0184 mL
		5 mM		0.4004 mL	2.0018 mL	4.0037 mL
10 mM			0.2002 mL	1.0009 mL	2.0018 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.5 mg/mL (5.00 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	CDK9-IN-1 is a novel, selective CDK9 inhibitor for the treatment of HIV infection, with an IC ₅₀ of 39 nM for CDK9/CycT1, extracted from reference, compound 87.
IC ₅₀ & Target	CDK9/CycT1 39 nM (IC ₅₀)
In Vitro	CDK9-IN-1 is a potent CDK9 inhibitor that shows high activity against HIV-1 replication ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

-
- Mol Immunol. 2021 May 11;135:351-364.
 - Harvard Medical School LINCS LIBRARY

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Nemeth G, et al. Novel, selective CDK9 inhibitors for the treatment of HIV infection. Curr Med Chem. 2011;18(3):342-358.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA